NDAOPHTHALMICIMPLANT
Approved
Mar 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
DURYSTA (bimatoprost) by AbbVie is bimatoprost, a prostaglandin analog, is a synthetic structural analog of prostaglandin with ocular hypotensive activity. Approved for ocular hypertension, open-angle glaucoma, glaucoma and 1 more indications. First approved in 2020.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DURYSTA is a bimatoprost intracameral implant approved in 2020 for treating ocular hypertension, open-angle glaucoma, and glaucoma suspects. It is a prostaglandin analog that lowers intraocular pressure by increasing aqueous humor outflow through both conventional and unconventional pathways. The implant-based delivery represents a novel formulation innovation for a established pharmacophore.
$0.965MPart D
Peak8.5 years to LOEEarly-stage commercial product with modest Part D penetration; smaller team structure compared to AbbVie's blockbuster ophthalmology franchises.
Mechanism of Action
Bimatoprost, a prostaglandin analog, is a synthetic structural analog of prostaglandin with ocular hypotensive activity. Bimatoprost is believed to lower IOP in humans by increasing outflow of aqueous humor through both the trabecular meshwork (conventional) and uveoscleral routes (unconventional).…
Pharmacologic Class:
Prostaglandin Analog
Indications (4)
Worked on DURYSTA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.